A 2023 meta-analysis of 11 randomized controlled trials found that GLP-1 monotherapy achieved average body weight reductions of 1222%, with improvements in blood glucose control, blood pressure, and cholesterol profiles as secondary benefits
medicine more sustainable. Why This GLP-1 Discount Matters GLP-1 medications like Wegovy and Zepbound have proven effective in helping patients manage diabetes and lose weight and may have additional health benefits, as well
They are not the same as, equivalent to, or generic versions of Ozempic, Wegovy, Mounjaro, or Zepbound
If Novo Nordisk demonstrates adequate supply and the FDA removes semaglutide from the shortage list, the legal framework for compounding it narrows significantly, similar to what has already happened with tirzepatide